Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.

Journal Article

Full Text

Duke Authors

Cited Authors

  • Rondeau, E; Scully, M; Ariceta, G; Barbour, T; Cataland, S; Heyne, N; Miyakawa, Y; Ortiz, S; Swenson, E; Vallee, M; Yoon, S-S; Kavanagh, D; Haller, H; 311 Study Group,

Published Date

  • May 1, 2021

Published In

Volume / Issue

  • 99 / 5

Start / End Page

  • 1244 -

PubMed ID

  • 33892867

Electronic International Standard Serial Number (EISSN)

  • 1523-1755

Digital Object Identifier (DOI)

  • 10.1016/j.kint.2021.03.008


  • eng

Conference Location

  • United States